Allogene Therapeutics, Inc. ALLO
1.65
(0.02)
(1.20%)
as of 25 Sep
- Market cap
- $594.2M
- P/E
- 0.0×
Follow ALLO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
— | 4,769.53 | 5,979.93 | 5,285.44 | 17.76 | — | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/Operating CF |
— | (11.31) | (10.58) | (13.28) | (44.60) | — | — | — | — |
P/B ratio |
— | 0.98 | 1.11 | 1.24 | 2.19 | — | — | — | — |
Price to Tangible BV |
— | 0.98 | 1.11 | 1.24 | 2.19 | — | — | — | — |
EV/Sales |
— | 1,407.74 | 1,256.80 | 1,969.28 | 13.75 | — | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
— | (0.61) | (0.50) | (1.39) | (8.49) | — | — | — | — |
EV/FCF |
— | (0.61) | (0.50) | (1.36) | (7.61) | — | — | — | — |
Quick Ratio |
7.70 | 8.23 | 12.10 | 9.63 | 9.55 | 8.78 | 16.04 | 15.59 | 0.00 |
Current Ratio |
7.93 | 8.54 | 12.38 | 9.84 | 9.84 | 8.96 | 16.46 | 15.89 | 0.00 |
Net Debt/EBITDA |
1.24 | 1.09 | 1.40 | 1.63 | 2.81 | 3.35 | 2.65 | 2.39 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.78 | 0.78 | 0.73 | 0.65 | 1.02 | 0.36 | 0.74 | 0.21 | 0.00 |
Capex/Depreciation |
(0.05) | (0.13) | (0.21) | (0.30) | (1.23) | (6.09) | (35.49) | (11.49) | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (53.42%) | (55.13%) | (55.51%) | (42.76%) | (18.16%) | (37.03%) | (27.71%) | (60.16%) | 0.00% | |
| (39.58%) | (43.24%) | (44.70%) | (36.36%) | (15.98%) | (32.52%) | (24.75%) | (54.66%) | 0.00% | |
ROIC |
(309.04%) | (131.65%) | (322.39%) | (140.22%) | (24.07%) | (64.12%) | (128.19%) | (49.44%) | 0.00% |
Return on Tangible Assets |
(64.04%) | (72.78%) | (62.75%) | (57.90%) | (33.32%) | (36.38%) | (32.50%) | (47.30%) | 100.00% |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 874,086.36% | 255,698.95% | 164,350.64% | 192.99% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 296,386.36% | 75,445.26% | 50,836.54% | 64.95% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 235,195.45% | 69,422.11% | 53,589.74% | 70.84% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
— | 0.43 | 0.58 | 0.45 | 0.17 | — | — | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
— | (62.44%) | (57.73%) | (40.28%) | (12.67%) | — | — | — | — |
Free Cash Flow Yield |
— | (48.44%) | (42.11%) | (27.37%) | (10.18%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.68) | (1.03) | (1.51) | (1.54) | (1.36) | (0.96) | (1.36) | (1.54) | 0.00 |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.04) | (0.16) | (0.55) | (0.50) | (0.18) | 0.00 |
Free Cash Flow per Share |
(0.68) | (1.03) | (1.52) | (1.58) | (1.52) | (1.50) | (1.86) | (1.73) | 0.00 |
Cash per Share |
1.13 | 1.50 | 2.86 | 3.61 | 3.37 | 6.88 | 5.25 | 15.87 | 0.00 |
Shareholders Equity per Share |
1.33 | 2.17 | 3.26 | 4.66 | 6.81 | 8.97 | 6.22 | 24.29 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.33 | 2.17 | 3.26 | 4.66 | 6.81 | 8.97 | 6.22 | 24.29 | 0.00 |
Free Cash Flow |
(149.63) | (200.99) | (239.25) | (225.71) | (206.26) | (181.05) | (188.14) | (49.98) | 0.00 |
Working Capital |
225.24 | 267.86 | 422.04 | 475.10 | 423.42 | 750.81 | 511.50 | 438.52 | 0.00 |
Capital Expenditures |
(0.39) | (0.69) | (1.52) | (5.19) | (21.45) | (65.96) | (50.79) | (5.33) | 0.00 |
Net Current Asset Value |
134.39 | 176.86 | 328.51 | 374.13 | 345.70 | 696.92 | 455.80 | 397.29 | 0.00 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.00 | 31.55 | 15.96 | 33.28 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | (1,170,863.64%) | (344,489.47%) | (218,214.10%) | (159.57%) | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.11 | 0.06 | 0.07 | 0.15 | 0.14 | 0.09 | 0.03 | 0.05 | 0.00 |
Cash ROIC |
(40.92%) | (40.07%) | (35.09%) | (28.15%) | (22.26%) | (12.26%) | (16.71%) | (4.58%) | 0.00% |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.03 | 25.35 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 4.50 | 4.50 | 2.50 | 2.50 | 2.50 | — |
Average Payables |
4.83 | 5.65 | 9.89 | 12.07 | 10.32 | 9.82 | 10.79 | 10.50 | — |
Average Assets |
482.31 | 595.77 | 732.21 | 936.20 | 1,139.33 | 972.82 | 745.83 | 386.93 | 387.00 |
Average Common Equity |
357.36 | 467.21 | 589.56 | 796.04 | 1,002.41 | 854.32 | 666.09 | 351.58 | 351.50 |
Columns are period end dates